Driven by GLP-1 shortages and FDA compounding restrictions, a multi-billion-dollar gray market for injectable peptides ...
Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds - Novo Nordisk claims ...
Novo Nordisk filed a lawsuit against Eli Lilly that alleges advertising falsely claims Wegovy is weaker than it is.
For Medicare beneficiaries prescribed a glucagon-like petide-1 (GLP-1) receptor agonist, eligibility rules are far from ...
Medicare's new GLP-1 Bridge program offers weight-loss drugs for $50 a month, but the copay sidesteps Part D's cap and Extra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results